ClinicalTrials.gg
CompletedNCT05088655Updated Dec 4, 2023

A Bioequivalence Study of Hetrombopag in Healthy Subjects

A Phase 1 interventional study of Hetrombopag Olamine Tablet in Sever Aplastic Anaemia, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2023-12-04.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jun 2021, registered Oct 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 88 studies in Anemia, Aplastic with a site in China — 39 open to participants now, 43 under way, 1 of them phase 3. Anemia, Aplastic · China.

Enrollment
31st of 74
58 · median 52
Started
2021
with 5 others
Phase 1
7 of 88
1 open now
Registered
32nd of 88
by date
Lead sponsor
7 of 88
Jiangsu HengRui Medicine Co., Ltd.

Among the 88 studies in Anemia, Aplastic with a site in China, this one is the 31st largest by enrollment of the 74 interventional ones that give a count, is one of 6 that started in 2021, is one of 7 in phase 1, and was the 32nd registered.

Anemia, Aplastic

372 studies on the registry are indexed under Anemia, Aplastic; 99 are open to participants now.

Browse Anemia, Aplastic studies →

Open to participants now

39 of the 88 studies in Anemia, Aplastic with a site in China are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 59 Anemia, Aplastic studies recruiting now, 21 (36%) set no upper age limit and 30 (51%) stop at 75 or younger; 38 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Anemia, Aplastic with a site in China, or all of them as a file.
02

Study summary

This study consists of two parts. Part 1 is a pilot BE study, and Part 2 is a pivotal study to demonstrate the bioequivalence of test and reference formulation, both of which adopt a single-center, randomized, open-label, three-period crossover design.

03

Conditions studied

  • Sever Aplastic Anaemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign the before the trial, and fully understand the trial content, process and possible adverse reactions;
  2. Ability to complete the study as required by the protocol;
  3. Healthy male or female subjects aged 18 to 45 (including 18 and 45) at the date of signing the informed consent;
  4. (BMI) within the range of 19 \~ 26 kg /m2 (including 19 and 26);

Exclusion criteria

Exclusion Criteria:

  1. Allergic constitution;
  2. History of drug use, or drug abuse screening positive;
  3. Alcoholic or often drinkers;
  4. History of deep vein thrombosis, or any other thromboembolic event;
  5. A clear medical history of important primary organ diseases such as nervous system, cardiovascular system, urinary system, digestive system, respiratory system, metabolism and musculoskeletal system.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Treatment group A: T - R- R

    Drug: Hetrombopag Olamine Tablet

  • Experimental
    Treatment group B: R -T - R

    Drug: Hetrombopag Olamine Tablet

  • Experimental
    Treatment group C: R- R-T

    Drug: Hetrombopag Olamine Tablet

Interventions

  • Hetrombopag Olamine Tablet (T: test formulation) Hetrombopag Olamine Tablet (R: reference formulation)

06

What researchers measure

Primary outcomes

  1. Peak plasma concentration (Cmax)

    Time frame: 0-120 hours post dose

  2. Area Under the plasma concentration vs time curve (AUC0-120)

    Time frame: 0-120 hours post dose

  3. area under the plasma concentration vs time curve (AUC0-inf)

    Time frame: 0-infinity

Secondary outcomes

  1. Time to Reach Maximum Drug Concentration in Plasma After Single Dose (Tmax)

    Time frame: 0-120 hours post dose

  2. Half-life Associated With the Terminal Slope (t½)

    Time frame: 0-120 hours post dose

  3. The number of volunteers with adverse events as a measure of safety and tolerability

    Time frame: up to Day 26

07

Study locations

1 site
  • The People's Hospital Of Liaoning Province
    Shenyang, Liaoning 110016, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Jul 2022, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2021
First posted
Oct 22, 2021
StartActual
Jun 25, 2021
Primary completionActual
Jul 25, 2022
CompletionActual
Nov 2, 2023
Last update
Dec 4, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05088655
Responsible party
Sponsor
First posted
Oct 22, 2021
Start date
Jun 25, 2021
Primary completion
Jul 25, 2022
Completion
Nov 2, 2023
Last update
Dec 4, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hetrombopag olamine

Start the discussion